- Home
- PIII vs AKTX Comparison
PIII vs AKTX Comparison
Compare PIII & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | AKTX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 14.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIII | AKTX |
|---|---|---|
| Price | $4.95 | $0.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.25 | $3.30 |
| AVG Volume (30 Days) | 10.6K | ★ 1.4M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.97 | $0.26 |
| 52 Week High | $14.50 | $1.73 |
Technical Indicators
Market Signals| Indicator | PIII | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.39 | 39.04 |
| Support Level | $5.01 | $0.26 |
| Resistance Level | $5.43 | $0.47 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 0.00 | 38.34 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.